ILB-2109

Overview

ILB-2109 is a selective antagonist of the adenosine A2A receptor (ADORA2A), which suppresses T-cell effector function in adenosine-rich tumor microenvironments. It is evaluated in combination with toripalimab (anti-PD-1) in nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• ILB-2109 selective A2AR antagonist + toripalimab under investigation in phase Ib/IIa for recurrent/metastatic NPC; targets adenosine-mediated T-cell suppression in the immunosuppressive NPC tumor microenvironment PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.